Company: PSTV
Filing Date: 2025-08-04
Form Type: DRS
Source: 0000950123-25-006916
Chunk: 3

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-08-04
Form: DRS
Chunk 3
---
 “Additional Commitment
Fee Trigger Date”), as consideration for its irrevocable commitment to purchase up to the Additional Available Amount of shares of our common stock at our direction under the Purchase Agreement, we will then pay Lincoln Park an additional
commitment fee of $500,000 (the “Additional Commitment Fee”) in cash or, if we comply with certain requirements set forth in the Purchase Agreement, by issuing shares of our common stock with a per share value calculated in accordance with
the Purchase Agreement (such shares, the “Additional Commitment Shares”), or any combination thereof. See “The Lincoln Park Transaction” for a description of the Purchase Agreement and “Selling Stockholder” for
additional information regarding Lincoln Park.

The selling stockholder may sell or otherwise dispose of the shares of common stock
described in this prospectus in a number of different ways and at varying prices. See “Plan of Distribution” for more information about how the selling stockholder may sell or otherwise dispose of the common stock being registered pursuant
to this prospectus. The selling stockholder is an “underwriter” within the meaning of Section 2(a)(11) of the Securities Act of 1933, as amended (the “Securities Act”).

The selling stockholder will pay all brokerage fees and commissions and similar expenses in connection with any resale or disposition of the
shares of common stock described in this prospectus by the selling stockholder. We will pay the expenses incurred in registering under the Securities Act the offer and sale of the shares of common stock to which this prospectus relates by the
selling stockholder, including legal and accounting fees. See “Plan of Distribution”.

Our common stock is currently listed on the
Nasdaq Capital Market (“Nasdaq”) under the symbol “PSTV”. On [ ], 2025, the closing price of our common stock, as reported on Nasdaq, was $[ ] per share.

Investing in our securities involves a high degree of risk. These risks are described in the “ Risk Factors” section on page 4 of this prospectus. You should also consider the risk factors described or referred to in any documents incorporated by reference in this prospectus, and in any applicable prospectus supplement, before investing in these securities.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

The date of this prospectus is , 202